Ruxolitinib phosphate cream, as the first and only targeted drug approved in China for the treatment of vitiligo, marked a key milestone in its expansion into multiple therapeutic areas with the acceptance of its NDA for the additional indication of AD. The NDA has been included in the Priority Review List based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”which is expected to accelerate the Product’s review process for marketing approval. Ruxolitinib phosphate cream has achieved positive results in the China Phase III clinical trial for AD: At Week 8, 63.0% of subjects achieved IGA 0/1, with ≥2 grades of reduction from baseline (vs. 9.2% for placebo, P < 0.001); 78.0% of subjects achieved EASI 75 (vs. 15.4% for placebo, P < 0.001). Overall, ruxolitinib phosphate cream was safe and well-tolerated. For AD, Dermavon has developed a comprehensive “treatment […]
Lidoderm® Lidocaine Cataplasms was approved for marketing in China in 2024, and its use for postherpetic neuralgia (PHN) treatment has been supported by consensus in clinical practice guidelines both in China and abroad Leveraging the advantages of its original brand, the Product can form in-depth synergy with the Group’s existing products in terms of expert resources and marketing channels; meanwhile, the Group will actively develop diverse marketing models such as new retail, further accelerating the development of the out-of-hospital market China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 12 February 2026, the Group through subsidiaries of the Company entered into an exclusive distribution agreement (the “Agreement”) with Teikoku Pharma USA, Inc. (“TPU”, a subsidiary of Japan-based Teikoku Seiyaku Co., Ltd (“TSC”), collectively referred to as the “Cooperation Partner”) for Lidoderm® Lidocaine Cataplasms (the “Product”). In accordance with […]
